JP2017517568A5 - - Google Patents

Download PDF

Info

Publication number
JP2017517568A5
JP2017517568A5 JP2017513618A JP2017513618A JP2017517568A5 JP 2017517568 A5 JP2017517568 A5 JP 2017517568A5 JP 2017513618 A JP2017513618 A JP 2017513618A JP 2017513618 A JP2017513618 A JP 2017513618A JP 2017517568 A5 JP2017517568 A5 JP 2017517568A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
seq
antibody
composition according
nervous system
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017513618A
Other languages
English (en)
Japanese (ja)
Other versions
JP6768639B2 (ja
JP2017517568A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/032134 external-priority patent/WO2015179737A2/en
Publication of JP2017517568A publication Critical patent/JP2017517568A/ja
Publication of JP2017517568A5 publication Critical patent/JP2017517568A5/ja
Priority to JP2020158560A priority Critical patent/JP7846960B2/ja
Application granted granted Critical
Publication of JP6768639B2 publication Critical patent/JP6768639B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017513618A 2014-05-23 2015-05-22 好酸球又はマスト細胞関連障害の治療 Active JP6768639B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2020158560A JP7846960B2 (ja) 2014-05-23 2020-09-23 好酸球又はマスト細胞関連障害の治療

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462002395P 2014-05-23 2014-05-23
US62/002,395 2014-05-23
US201562162538P 2015-05-15 2015-05-15
US62/162,538 2015-05-15
PCT/US2015/032134 WO2015179737A2 (en) 2014-05-23 2015-05-22 Treatment of eosinophil or mast cell related disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020158560A Division JP7846960B2 (ja) 2014-05-23 2020-09-23 好酸球又はマスト細胞関連障害の治療

Publications (3)

Publication Number Publication Date
JP2017517568A JP2017517568A (ja) 2017-06-29
JP2017517568A5 true JP2017517568A5 (https=) 2018-06-28
JP6768639B2 JP6768639B2 (ja) 2020-10-21

Family

ID=54554980

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017513618A Active JP6768639B2 (ja) 2014-05-23 2015-05-22 好酸球又はマスト細胞関連障害の治療
JP2020158560A Active JP7846960B2 (ja) 2014-05-23 2020-09-23 好酸球又はマスト細胞関連障害の治療
JP2023132592A Pending JP2023154065A (ja) 2014-05-23 2023-08-16 好酸球又はマスト細胞関連障害の治療

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020158560A Active JP7846960B2 (ja) 2014-05-23 2020-09-23 好酸球又はマスト細胞関連障害の治療
JP2023132592A Pending JP2023154065A (ja) 2014-05-23 2023-08-16 好酸球又はマスト細胞関連障害の治療

Country Status (5)

Country Link
US (4) US10239943B2 (https=)
EP (1) EP3145543A4 (https=)
JP (3) JP6768639B2 (https=)
CN (3) CN113908269A (https=)
WO (1) WO2015179737A2 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9540443B2 (en) 2011-01-26 2017-01-10 Kolltan Pharmaceuticals, Inc. Anti-kit antibodies
CN116574185A (zh) 2012-07-25 2023-08-11 塞尔德克斯医疗公司 抗kit抗体及其用途
CN113908269A (zh) 2014-05-23 2022-01-11 塞尔德克斯医疗公司 嗜酸性粒细胞或肥大细胞相关病症的治疗
WO2018017569A1 (en) * 2016-07-19 2018-01-25 Arete Discoveries, Inc. Biomarkers for detection and treatment of mast cell activity-associated disorders
US11167023B2 (en) * 2018-12-28 2021-11-09 DANCLAY Properties, LLC Method of treating mammals displaying severe neurological symptoms of advanced canine distemper virus infection using NDV-induced serum
CA3207070A1 (en) * 2021-01-22 2022-07-28 Celldex Therapeutics, Inc. Anti-kit antibodies and uses thereof
EP4281113A4 (en) * 2021-01-22 2024-11-20 Celldex Therapeutics, Inc. TREATMENT OF CHRONIC PRURIGO
WO2022182982A1 (en) * 2021-02-26 2022-09-01 Third Harmonic Bio, Inc. Methods for treating c-kit kinase mediated diseases and disorders using a selective c-kit kinase inhibitor

Family Cites Families (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5268358A (en) 1988-12-08 1993-12-07 Cor Therapeutics, Inc. PDGF receptor blocking peptides
US7144731B2 (en) 1989-10-16 2006-12-05 Amgen Inc. SCF antibody compositions and methods of using the same
US20050276784A1 (en) 1990-08-27 2005-12-15 Solan-Kettering Institute For Cancer Research Ligand for the c-kit receptor and methods of use thereof
US20030125519A1 (en) 1990-08-27 2003-07-03 Peter Besmer Ligand for the c-kit receptor and methods of use thereof
ES2147729T3 (es) 1991-01-31 2000-10-01 Cor Therapeutics Inc Dominios de la region extracelular de polipeptidos receptores de factor de crecimiento derivado de plaquetas humano.
DK0578774T3 (da) 1991-04-05 1999-04-26 Univ Washington Monoklonale antistoffer mod stamcellefaktor-receptorer
US5545533A (en) 1991-05-25 1996-08-13 Boehringer Mannheim Gmbh Monoclonal antibodies against c-kit and method of detecting a malignancy using c-kit specific antibodies
DE4205148A1 (de) 1991-05-25 1993-01-21 Boehringer Mannheim Gmbh Monoklonale antikoerper gegen c-kit
EP0619738B1 (en) 1991-12-02 2003-07-09 Millennium Pharmaceuticals, Inc. Inhibitory immunoglobulin polypeptides to human pdgf beta receptor
US5817310A (en) 1991-12-02 1998-10-06 Cor Therapeutics, Inc. Inhibitory immunoglobulin polypeptides to human PDGF beta receptor
EP0548867A2 (en) 1991-12-23 1993-06-30 Yeda Research And Development Co. Ltd. Soluble stem cell factor (SFC)-receptor
US6001803A (en) 1992-04-23 1999-12-14 Sloan-Kettering Institute For Cancer Research Composition of c-kit ligand, GM-CSF, and TNF-α and method of use
US6448077B1 (en) 1994-02-10 2002-09-10 Imclone Systems, Inc. Chimeric and humanized monoclonal antibodies specific to VEGF receptors
US5911988A (en) 1995-04-28 1999-06-15 Bayer Corporation Method for treating asthma using SCF antibody
US6936259B2 (en) 1995-06-08 2005-08-30 University Of Saskatchewan CAMP factor of Streptococcus uberis
DE19600589C1 (de) 1996-01-10 1997-01-16 Univ Eberhard Karls Antikörper A3C6E2
US5882644A (en) 1996-03-22 1999-03-16 Protein Design Labs, Inc. Monoclonal antibodies specific for the platelet derived growth factor β receptor and methods of use thereof
US5910417A (en) 1996-05-31 1999-06-08 National Jewish Center For Immunology And Respiratory Medicine Regulation of cytokine production in a hematopoietic cell
AU6763098A (en) 1997-03-19 1998-10-12 Yale University Methods and compositions for stimulating apoptosis and cell death or for inhibiting cell growth and cell attachment
DE19727814C1 (de) 1997-06-30 1998-10-01 Univ Eberhard Karls Anitkörper 4G8B4B12
US7361336B1 (en) 1997-09-18 2008-04-22 Ivan Bergstein Methods of cancer therapy targeted against a cancer stem line
AU9692498A (en) 1997-10-10 1999-05-03 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Complex of biotinylated viral vector and ligand for targeted gene delivery
WO2000061637A1 (en) 1999-04-14 2000-10-19 Smithkline Beecham Corporation Erythropoietin receptor antibodies
US6576812B1 (en) 1999-05-06 2003-06-10 The Trustees Of Columbia University In The City Of New York Compound screening assays using a transgenic mouse model of human skin diseases
US6989248B2 (en) 1999-05-06 2006-01-24 The Trustees Of Columbia University In The City Of New York Methods of use of compounds which inhibit the stem cell signaling pathway
EP1227846A2 (en) 1999-11-12 2002-08-07 ADVANCED RESEARCH AND TECHNOLOGY INSTITUTE, Inc. Methods for inhibiting neurofibromatosis type 1 (nf1)
EP1255536B1 (en) * 1999-12-22 2006-06-28 Sugen, Inc. Indolinone derivatives for modulation of c-kit tyrosine protein kinase
US8088060B2 (en) 2000-03-15 2012-01-03 Orbusneich Medical, Inc. Progenitor endothelial cell capturing with a drug eluting implantable medical device
US20110091428A1 (en) 2000-07-31 2011-04-21 New York Medical College Compositions of adult organ stem cells and uses thereof
US6914947B2 (en) 2001-02-28 2005-07-05 Telefonaktiebolaget L M Ericsson (Publ) Method and apparatus for handling time-drift
WO2002084290A1 (fr) 2001-04-13 2002-10-24 Chugai Seiyaku Kabushiki Kaisha Procede permettant de quantifier l'expression d'antigenes
JP2003048831A (ja) 2001-08-02 2003-02-21 Suntory Ltd 脳機能の低下に起因する症状あるいは疾患の予防又は改善作用を有する組成物
EP2277991A1 (en) 2001-08-21 2011-01-26 Ventana Medical Systems, Inc. Method and quantification assay for determining c-kit/SCF/pAKT status
CA2471140A1 (en) 2001-12-20 2003-07-03 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to trail receptors
US6998391B2 (en) 2002-02-07 2006-02-14 Supergen.Inc. Method for treating diseases associated with abnormal kinase activity
AU2003217912A1 (en) 2002-03-01 2003-09-16 Xencor Antibody optimization
AU2003237332A1 (en) 2002-06-03 2003-12-19 Centocor, Inc. Anti-relp fusion antibodies, compositions, methods and uses
WO2004002425A2 (en) 2002-06-28 2004-01-08 Bio Transplant, Inc. Process for promoting graft acceptance by depletion of hematopoietic stem cells
CA2514979A1 (en) 2003-01-31 2004-09-02 Celldex Therapeutics, Inc. Antibody vaccine conjugates and uses therefor
US20050281828A1 (en) 2003-03-04 2005-12-22 Bowdish Katherine S Method of treating autoimmune disease by inducing antigen presentation by tolerance inducing antigen presenting cells
WO2005003302A2 (en) * 2003-06-17 2005-01-13 Medimmune, Inc. Novel methods to modulate mast cells
US7303893B1 (en) 2003-08-28 2007-12-04 Takeda San Diego, Inc. Crystallization of c-KIT tyrosine kinase leading to autoinhibited crystal structure
US8133733B2 (en) 2003-10-24 2012-03-13 Gencia Corporation Nonviral vectors for delivering polynucleotides to target tissues
WO2005057223A2 (en) 2003-12-04 2005-06-23 Applied Research Systems Ars Holding N.V. Methods for identifying modulators of active kit tyrosine kinase receptor
MX350383B (es) 2004-01-09 2017-09-04 Pfizer Anticuerpos contra madcam.
DE112005001317A5 (de) 2004-03-27 2007-05-24 Klein, Hanns-Georg, Dr. Polymorphismen im NOD2/Card15 Gen
ES2375481T3 (es) 2004-03-30 2012-03-01 Yissum Research Development Company Of The Hebrew University Of Jerusalem Anticuerpos biespecíficos para elegir como diana células que participan en reacciones de tipo alérgico, composiciones y usos de los mismos.
CN1997382A (zh) 2004-05-05 2007-07-11 梅里麦克制药股份有限公司 调节生物活性的双特异性结合剂
US7329495B2 (en) 2004-06-09 2008-02-12 Board Of Regents, The University Of Texas System Mutations in KIT confer imatinib resistance in gastrointestinal stromal tumors
CA2570817A1 (en) * 2004-06-17 2006-01-26 Plexxikon, Inc. Azaindoles modulating c-kit activity and uses therefor
AU2005271892A1 (en) 2004-07-10 2006-02-16 Alexion Pharmaceuticals, Inc. Methods for discovering antibodies specific to cancer cells and antibodies discovered thereby
PL1781321T3 (pl) 2004-08-02 2014-07-31 Zenyth Operations Pty Ltd Sposób leczenia raka zawierający antagonistę VEGF-B
CA2575791A1 (en) 2004-08-03 2006-02-16 Dyax Corp. Hk1-binding proteins
CA2599606A1 (en) 2005-02-23 2006-08-31 Merrimack Pharmaceuticals, Inc. Bispecific binding agents for modulating biological activity
US20060222634A1 (en) 2005-03-31 2006-10-05 Clarke Diana L Amnion-derived cell compositions, methods of making and uses thereof
CA2606081C (en) 2005-04-26 2013-09-17 Markus M. Heiss Combination of the application of antibodies for immunostimulation together with glucocorticoids
AU2006264567A1 (en) 2005-05-05 2007-01-11 Valorisation Hsj, Societe En Commandite Cytokine receptor modulators and uses thereof
WO2007014943A2 (en) 2005-08-01 2007-02-08 Ares Trading S.A. Therapy for neurological diseases
WO2008048671A1 (en) 2006-10-18 2008-04-24 University Of Illinois Embryonic-like stem cells derived from adult human peripheral blood and methods of use
ES2577535T3 (es) 2005-10-21 2016-07-15 Regents Of The University Of California Mutaciones del oncogén de C-kit en melanomas
EP1790664A1 (en) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
US20090304625A1 (en) 2006-01-18 2009-12-10 Ahsan Husain Modulators of cardiac cell hypertrophy and hyperplasia
EP2606890A1 (en) 2006-04-05 2013-06-26 Novartis AG Combinations comprising BCR-ABL/C-KIT/PDGF-R TK inhibitors for treating cancer
TWI395754B (zh) 2006-04-24 2013-05-11 Amgen Inc 人類化之ｃ-ｋｉｔ抗體
JP2010500283A (ja) 2006-05-31 2010-01-07 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー チロシンキナーゼ阻害剤を用いて炎症性疾患を治療する方法
US7919092B2 (en) 2006-06-13 2011-04-05 Oncomed Pharmaceuticals, Inc. Antibodies to notch receptors
JP2009540018A (ja) 2006-06-13 2009-11-19 ザイモジェネティクス， インコーポレイテッド Ｉｌ−１７およびｉｌ−２３アンタゴニストならびにその使用方法
EA200900573A1 (ru) 2006-10-20 2009-10-30 АйАрЭм ЭлЭлСи Композиции и способы для модуляции рецепторов c-kit и pdgfr
US7959942B2 (en) 2006-10-20 2011-06-14 Orbusneich Medical, Inc. Bioabsorbable medical device with coating
ES2882360T3 (es) 2006-11-03 2021-12-01 Univ Leland Stanford Junior Inmunoempobrecimiento selectivo de un nicho de células madre endógenas para injerto
US20100029674A1 (en) 2006-11-17 2010-02-04 Innate Pharma, S.A. Methods of Using Phosphoantigen for the Treatment of Cancer
WO2008115300A1 (en) 2006-12-01 2008-09-25 Apocell, Inc. C-kit phosphorylation in cancer
JP5885012B2 (ja) * 2007-01-19 2016-03-15 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅＬＬＣ Ｋｉｔ阻害剤に対して獲得した抵抗性を有する癌の処置
CA2703136A1 (en) * 2007-03-12 2008-09-18 Vasgene Therapeutics, Inc. Use of ephb4 as a diagnostic marker and a therapeutic target for ovarian cancer
AU2008232354B9 (en) 2007-03-27 2012-07-26 Synta Pharmaceuticals Corp. Triazinone and diazinone derivatives useful as Hsp90 inhibitors
US20110268776A1 (en) 2007-04-25 2011-11-03 Schapira Jay N Programmed-release, nanostructured biological construct for stimulating cellular engraftment for tissue regeneration
HUE036885T2 (hu) * 2007-05-14 2018-08-28 Astrazeneca Ab Eljárás a bazofil-szint csökkentésére
AR066660A1 (es) 2007-05-23 2009-09-02 Genentech Inc Prevencion y tratamiento de condiciones del ojo asociadas con su complemento
CN101801407B (zh) 2007-06-05 2013-12-18 耶鲁大学 受体酪氨酸激酶抑制剂及其使用方法
WO2009021137A2 (en) 2007-08-07 2009-02-12 Purdue Research Foundation Kinase inhibitors and uses thereof
US20100196923A1 (en) 2007-08-14 2010-08-05 Anthony Atala Pluripotent adult stem cells
US8569262B2 (en) 2007-11-02 2013-10-29 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
WO2009073139A2 (en) 2007-11-28 2009-06-11 Osi Pharmaceuticals, Inc. Combined treatment with an egfr kinase inhibitor and an inhibitor of c-kit
WO2009082624A2 (en) 2007-12-10 2009-07-02 Zymogenetics, Inc. Antagonists of il-17a, il-17f, and il-23 and methods of using the same
AU2008338421A1 (en) 2007-12-17 2009-06-25 Dyax Corp. Compositions and methods for treating osteolytic disorders comprising MMP-14 binding proteins
US8426396B2 (en) 2008-01-08 2013-04-23 Shriners Hospitals For Children Treatment for achondroplasia
US20110059091A1 (en) 2008-02-04 2011-03-10 Xiao-Jia Chang Inhibitors of oncogenic isoforms and uses thereof
WO2009135001A2 (en) 2008-04-30 2009-11-05 University Of Pittsburgh- Commonwealth System Of Higher Education Methods and compositions for regulating th2 and th17 responses
EP2297305A4 (en) 2008-05-15 2013-03-13 Univ Miami ISOLATION OF STEM CELL PROCESSORS AND EXPANSION UNDER NON-TERMS OF CONDITION
MX2010013683A (es) * 2008-06-13 2011-04-26 Novartis Ag Bencimidazoles sustituidos para neurofibromatosis.
WO2009158447A2 (en) * 2008-06-27 2009-12-30 Indiana University Research And Technology Corporation Materials and methods for suppressing and/or treating neurofibroma and related tumors
KR20110039220A (ko) 2008-06-30 2011-04-15 교와 핫꼬 기린 가부시키가이샤 항ｃｄ27 항체
US20110293574A1 (en) 2008-09-26 2011-12-01 Chute John P Hematopoietic stem cell growth factor
MX2011004165A (es) 2008-10-22 2011-08-08 Genentech Inc Celulas madre de prostata y sus usos.
RU2015130665A (ru) 2008-11-19 2018-12-24 Антродженезис Корпорейшн Амниотические адгезивные клетки
WO2010065685A1 (en) 2008-12-04 2010-06-10 Cleveland Clinic Method of treating c-kit positive relapsed acute myeloid leukemia
US20100204058A1 (en) 2009-01-28 2010-08-12 Howard Yuan-Hao Chang Profiling for Determination of Response to Treatment for Inflammatory Disease
JP2012525149A (ja) 2009-04-27 2012-10-22 オンコメッド ファーマシューティカルズ インコーポレイテッド ヘテロ多量体分子を作製するための方法
PE20120475A1 (es) 2009-05-12 2012-05-05 Pfizer Anticuerpos especificos para dkk-1
KR101224468B1 (ko) 2009-05-20 2013-01-23 주식회사 파멥신 신규한 형태의 이중표적항체 및 그 용도
WO2010136508A2 (en) 2009-05-28 2010-12-02 Glaxo Group Limited Stem cell targeting
NZ599866A (en) * 2009-11-06 2014-09-26 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
IN2012DN05014A (https=) 2009-12-29 2015-10-02 Univ Yale
BR112012016992A2 (pt) 2010-01-14 2019-09-24 Univ Yale "funcionalidade que se liga a uma interface de contato assimétrico de um recpetor de tirosina quinase (rtk), hibridoma, composição farmacêutica, uso de uma quantidade efixaz da funcionalidade, método para identificar uma funcionalidade que se liga a uma interface de contato assimétrico de um receptor de tirosina quinase (rtk), e, molécula pequena".
US20130011406A1 (en) 2010-03-26 2013-01-10 Kolltan Pharmaceuticals, Inc. Anti-kit antibodies and uses thereof
AU2012204846B2 (en) 2011-01-06 2016-09-08 Complix Nv Alphabodies specifically binding to cytokines or growth factors and/or cytokine or growth factor receptors
US9540443B2 (en) 2011-01-26 2017-01-10 Kolltan Pharmaceuticals, Inc. Anti-kit antibodies
AR086044A1 (es) * 2011-05-12 2013-11-13 Imclone Llc Anticuerpos que se unen especificamente a un dominio extracelular de c-kit y usos de los mismos
JP6104257B2 (ja) 2011-10-14 2017-03-29 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ ピロロベンゾジアゼピンおよびそのコンジュゲート
WO2013177481A1 (en) 2012-05-25 2013-11-28 Immunogen, Inc. Benzodiazepines and conjugates thereof
CN116574185A (zh) 2012-07-25 2023-08-11 塞尔德克斯医疗公司 抗kit抗体及其用途
WO2015050959A1 (en) 2013-10-01 2015-04-09 Yale University Anti-kit antibodies and methods of use thereof
WO2015112822A1 (en) 2014-01-24 2015-07-30 Kolltan Pharmaceuticals, Inc. Antibody-drug conjugates targeting kit receptor and uses thereof
CN113908269A (zh) 2014-05-23 2022-01-11 塞尔德克斯医疗公司 嗜酸性粒细胞或肥大细胞相关病症的治疗

Similar Documents

Publication Publication Date Title
JP2017517568A5 (https=)
Dubois et al. Rilonacept and canakinumab
US20090123456A1 (en) Treatment of pancreatitis using alpha 7 receptor-binding cholinergic agonists
Liu et al. Bispecific antibody targeting TROP2xCD3 suppresses tumor growth of triple negative breast cancer
Chino et al. Tocilizumab monotherapy for polymyalgia rheumatica: A prospective, single‐center, open‐label study
Risitano et al. Alemtuzumab is safe and effective as immunosuppressive treatment for aplastic anaemia and single‐lineage marrow failure: a pilot study and a survey from the EBMT WPSAA
Vecchié et al. Interleukin-1 and the NLRP3 inflammasome in pericardial disease
Arora et al. Biological agents in gastrointestinal cancers: adverse effects and their management
Sweet Induction therapy in lung transplantation
Schwotzer et al. Daratumumab for relapsed or refractory AL amyloidosis with high plasma cell burden
Suzuki et al. Involvement of autophagy in exacerbation of eosinophilic airway inflammation in a murine model of obese asthma
Lobo et al. New prospects in the diagnosis and treatment of immune-mediated inner ear disease
Slemmons et al. LRRC15 antibody‐drug conjugates show promise as osteosarcoma therapeutics in preclinical studies
Liebman et al. Low‐dose anti‐CD 20 veltuzumab given intravenously or subcutaneously is active in relapsed immune thrombocytopenia: a phase I study
CN113056484A (zh) 阻断mica/b脱落的抗mica/b抗体及其使用方法
JP2022141801A (ja) 抗ｂｍｐ６抗体またはその抗原結合フラグメント、および組み合わせ物
Detroyer et al. Resolution of diffuse skin and systemic K aposi's sarcoma in a renal transplant recipient after introduction of everolimus: a case report
Srinivasan et al. Phase I study of the tolerability and pharmacokinetics of palifermin in children undergoing allogeneic hematopoietic stem cell transplantation
Khairallah et al. Tocilizumab for the treatment of chronic antibody mediated rejection in kidney transplant recipients
Chen et al. Metformin alleviates bevacizumab-induced vascular endothelial injury by up-regulating GDF15 and activating the PI3K/AKT/FOXO/PPARγ signaling pathway
Smolen et al. Efficacy and safety of CT-P47 versus reference tocilizumab: 32-week results of a randomised, active-controlled, double-blind, phase III study in patients with rheumatoid arthritis, including 8 weeks of switching data from reference tocilizumab to CT-P47
US12146001B2 (en) Treatment of allergic diseases with chimeric protein
CN119454695A (zh) Csf1r激酶抑制剂及其用途
Lu et al. Pharmacokinetics, pharmacodynamics, and safety of subcutaneous bapineuzumab: a single‐ascending‐dose study in patients with mild to moderate Alzheimer disease
Li et al. Combination therapy with DHA and BMSCs suppressed podocyte injury and attenuated renal fibrosis by modulating the TGF-β 1/Smad pathway in MN mice